艾迪药业：多替拉韦钠原料药获上市申请批准

Core Viewpoint - The approval of the chemical raw material drug, Dolutegravir Sodium, by the National Medical Products Administration is a significant milestone for the company, enhancing its competitive edge in the HIV treatment market [1] Group 1: Regulatory Approval - The company's wholly-owned subsidiary, Yangzhou Aidi Pharmaceutical Technology Co., Ltd., received the approval notice for the listing application of Dolutegravir Sodium on October 27, 2025 [1] - The registration number for the raw material drug is Y20240000542 [1] Group 2: Product Details - Dolutegravir Sodium is part of the company's fundraising project focused on the R&D of high-end generic drugs for HIV, specifically as a raw material for the formulation project ADC201 [1] - The drug is indicated for use in combination with other antiretroviral medications for the treatment of HIV infection in adults and children aged 12 and older [1] Group 3: Impact on the Company - The approval is expected to ensure the supply and quality of the raw material, reduce production costs, and enhance the company's core competitiveness [1] - It is anticipated that this approval will not have a significant impact on the company's recent operations [1]